Investors Contact

We are committed to maintaining relationships with our investors, shareholders and persons interested in investor relations information. Contact us.

Mateusz Sagan
Chief Business Officer / Supervisory Board Member


Experienced Senior Executive Manager / Chief Business Officer at SDS Optic
MBA graduate from University of Central Lancashire Preston, UK
Experienced Leader and Executive Management, specialized in strategic management, sales management, start-ups in different countries and cultures. Strong financial, ethics and compliance background, with personal capabilities developed with Dale Carnagie and Franklin Covey programs.
Strong Leadership and Vision building expertise.
Polish National Sales Awards referee; Business Centre Club member, TEDx speaker

Ownership structure

As of April 2019, Share Capital of SDS Optic represents 76.860 shares valued 3.843.000,00 PLN, each share valued at 50,00PLN. SDS Optic ownership structure consists of capital belong to: Magdalena Staniszewska, SDS Optonic LLC, Innoventure, Polish Entrerpreneurs Foundation.

Magdalena Staniszewska, PhD, DSc
Co-Founder, Chief Science Officer

235 500 shares valued 235.500,00 PLN – 6,1% in Share Capital

SDS Optonic LLC
a Special Purpose Vehicle (SPV), controlled and managed by Marcin Staniszewski, Co-Founder and CEO

2 400 000 shares valued 2.400.000,00 PLN – 62,5%

Majority of SDS Optonic LLC shares belong to Marcin Staniszewski. Remaining part of SDS Optonic LLC shares belong to 4 Business Angels, who invested at early startup phase.

INNOventure – venture capital fund from Cracov, Poland

INNOventure helps scientists, inventors and entrepreneurs develop business projects based on the results of research and development. INNOventure creates companies together with scientists, research institutes and investors. As a shareholder INNOventure provides not only financial capital, but also broad support in building valuable businesses

490 750 shares valued 407.500,00 PLN – 10,6%

Polska Fundacja Przedsiębiorczości

Polish Entrepreneurs Foundation (PFP) – seed fund from Szczecin, Poland

POMERANUS SEED is managed by Polish Entrepreneurs Foundation, one of the largest SME support organization in Poland.
The fund was launched in 2010 and actively invests in polish technology startups.
Initial capitalization was 18 mln zl. Currently the fund invests money coming from exits.

800 000 shares valued 800.000,00 PLN – 20,8%

Media about SDS Optic

SDS Optic is committed to providing the media with timely and accurate information. This section offers key resources for journalists, editors and other media professionals. Here you can read more about progress, and explore our recent announcements and resources.

Lubelscy naukowcy: Dzięki tej metodzie szybciej wykryjemy raka piersi

Unikalny projekt naukowców z Lublina. Dzięki niemu szybciej można wykryć raka piersi

Polski projekt przyszłością diagnostyki onkologicznej

Szybki test nowotworowy

Rewolucja w diagnostyce raka piersi – mikrosonda InProbe

Naukowcy z Lublina opracowali rewolucyjną metodę wykrywania raka piersi

Rewolucja w diagnostyce raka nadciąga z Lublina

Lubelscy naukowcy opracowali szybszą metodę wykrywania raka piersi

Polski projekt przyszłością diagnostyki onkologicznej

Lubelski wykrywacz raka

To urządzenie sprawdzi w kwadrans, czy nowotwór jest złośliwy

SDS Optic zdobywcą nagrody Wschodzące Technologie

Polska medycyna sięga po dane

Nowe technologie ratują życie

Sonda z Lublina skróci wykrycie raka piersi do 15 minut. Nadzieja dla pacjentów

PARP – Go to Brand

SDS Optic was granted from PARP Go to Brand programme for inPROBE promotion actions on foreign markets. Main aim of this grant is supporting promotion and internationalization inPROBE project.

Each of the Go To Brand payee has a promotion funding programme which indicates specific events (usually trade shows) at non-EU markets, where companies may promote their products. Individual promotional activities are thus linked with the national strategy of building repute and prestige of the Polish economy brand abroad.

The Polish Agency for Enterprise Development (PARP) is involved in the implementation of national and international programmes financed from the EU structural funds, state budget and multiannual programmes of the European Commission. As a key authority responsible for creating a business-friendly environment in Poland, PARP contributes to the creation and effective implementation of the state policy related to enterprise, innovation and staff adaptability. Pursuant to the principle “Think Small First”, in all its activities the Agency puts a particular emphasis on the needs of the SME sector.

NCBiR Strategmed

The Programme intends to face challenges of ageing society, the higher incidence of chronic diseases and in the end, to deal with the issue of rising medical service costs.

The key objective of the Programme is to achieve a significant progress in the treatment of civilization diseases and regenerative medicine on the basis of results achieved from research and development activities conducted in the following areas:

  1. Cardiology and cardiac surgery
  2. Oncology
  3. Neurology and senses
  4. Regenerative medicine

The Programme is to stimulate the innovation and competitiveness of Polish economy, particularly in biotechnology, biomedical engineering areas, by means of projects oriented to development and implementation of new methods used in the areas of: prevention, diagnosis, medical treatment and rehabilitation.  

Moreover, STRATEGMED will strengthen the international competitive position of Poland in the following areas: research and development activities in the scientific fields related to STRATEGMED, involvement of dynamic international teams of young researches and finally, know-how and new technologies transfer to the Polish economy.

Horizon 2020 SME Instrument

The European Commission has contributed to SDS Optic’s project “Revolutionary opto-biological methodology for aggressive HER2 cancer”. The startup from Lublin was granted €3.985.000 from the SME Instrument (Horizon 2020) programme to develop a revolutionary optical device OmiProbe for safe, fast and non-destructive cancer diagnosis.

As part of the Horizon 2020 programme, the European Commission is hand-picking potentially disruptive businesses to invest and support as part of the SME Instrument. In the latest phase (June 2017), 1514 projects applied for the financial support and only 57 (2 from Poland) got funding. The grant for SDS Optic is so far the largest for the polish company and also the largest in this phase of the programme. It will finance optimisation of the SDS-OmiProbe device, independent clinical trials, certification and commercialisation.

SDS Optic designed a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS inProbe detects presence and measures concentration levels of the HER+ cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs.

According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease. Current diagnosis methods of cancers fail to deliver objective results. Diagnosis requires extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which is subject to significant levels of discordance. Thanks to SDS-OmiProbe, the accurate result of the same analysis will be achievable in a few minutes. It will spare the patient’s pain and stress connected with biopsy and waiting for the results. It is planned that the first patients will be diagnosed using SDS inProbe in 2021.

Visit official website:

Our vision

Increasing the survival rate of cancer patients by 30% by 2030

SDS Optic S.A. creates and develops diagnostic and monitoring solutions, combining optoelectronics (photonics) with molecular biology, medical bioengineering and immunochemistry.

The mission of SDS Optic S.A. is one of the main objectives that many countries and international organizations have committed themselves to achieving. On 4 February 2017, on World Cancer Day, the World Health Organization published a new list of recommended medical procedures and services, that are required at an early stage of cancer development, to increase the chances of curing the patients.

According to the WHO, it is necessary to intensify the global development of diagnostic solutions that can be applied at the very beginning of the diagnostic pathway for people with suspected cancer.

Many countries have committed themselves to the Sustainable Development Goals (SDGs). One of the points of this agenda is to reduce premature deaths caused by cancer by 1/3 by 2030.

Our mission and objective
is to increase the survival
of cancer patients
by 30% by 2030.

Urządzenie inPROBE - wizja SDS Optic S.A.

WHO is not the only international institution that, like SDS Optic, wishes to fight for the life of cancer patients. The objective of improving the quality of life and extending the life expectancy of 3 million people by 2030 through prevention and treatment, and supporting cancer patients and their families, was also included in the European Commission’s Horizon Europe document.

SDS Optic S.A. consciously the mission of increasing cancer survival by 30% by 2030 in its DNA. Research, reports and the direction of development of global and renowned organizations indicate that effective solutions for the diagnosis of diseases at the earliest possible stage can save human life and health.

That’s why we created inPROBE – a micron optical biosensor for the detection of bioelements in real time, in vivo (inside the human body). You can find more on how our technology works at

Medical devices

inPROBE – disruptive platform technology with global potential to challenge the paradigm of targeted biology diagnostics and real-time targeted drugs delivery monitoring

Nowadays millions of people die each year from cancer. It’s a medical professionals to save lives of patients worldwide.At the same time the future of cancer therapies is here now, several targeted or gene therapies are gaining trust, but their efficiency is strictly depends on proper and real time targeted tumor biology diagnostics, which doeas not exist yet. That’s why we’ve invented and developed inPROBE, a platform technology which links targeted therapies with targeted diagnostics.Our technology will reduce diagnosis time, increase precision and improve the effects of innovative cancer treatments. It can be used both in cancer diagnostics and therapies monitoring in real time and in a natural state, thus giving medical professionals a previously unavailable fast and efficient tool.

Key benefits

How it works

inPROBEis a nano-size glass probe placed in vivo inside a very thin biopsy needle, connected to a detecting device and with innovative components on a probe tip. Thanks to it’s thickness it is safer, much less stressful and much less painful.Fast and precise cancer diagnosis combined with modern therapies can help to SAVE UP TO 30% of people diagnosed with cancer by 2030.The high sensitivity of inProbe enables it into examine even single cells. It also allows to close access to the tumor without the need to get into the tumor as today, which can lead to malignant cancer.

All the data gathered during the procedure is transferred via fiber optics into the multi- purpose detecting device. The data is then calculated using specific algorithms and presented to the oncologist as a diagnostic result – a numerical measurement with exact level of tested components (e.g. HER2 cancer biomarker).

During cancer therapies inProbe will be able to measure the level of active ingredients (e.g. Trastuzumab) in cancer tumor cells, thus supporting & improving the efficiency of modern targeted cancer therapies and patients’ well-being.


SDS-MicroProbe can be a groundbreaking solution to overcome problems in current technology and enable analysis of biological processes inside the single cell in their natural state. As an expert in hematology, I am convinced that such solution would find several applications in research as well as in future cell therapies in the cancer area.

Hematologist/Oncologist M.D. PhD
with several years of scientific experience at NIH
Bethesda, MD, USA

There is an unmet need to study biological processes within individual cells residing in their native niche. The SDS-MicroProbe addresses this shortcoming; it is a new approach in analyzing key intracellular parameters that indicate the functionality of a cell. The SDS-MicroProbe has the potential to substantially advance our ability to assess the status of living cells and thereby improve our ability to diagnose various diseases and evaluate the efficiency of interventions.

Professor, PhD of Harvard Medical School
Boston, MA, USA


If you want to know more about our project, you can download the newest brochure here or visit our website